Back Bay
Read more
Creation House
Creation House
Funding
Convertible loan of 1,3M euros (10M DKK)
Purpose
Maturation of project to attract funding
Eligibility
Established proof of concept and initial business plan
Key Outcome
A prototype or lead candidate
Duration
Up to 18 months
Location
BioInnovation Institute in Copenhagen, Denmark
Approvers
The BII board of directors
Open Calls
Up to seven loans granted per open call
The Creation House program
Creation House is for companies with a solid, initial business plan. In the therapeutic area, a cellular proof of concept with chemical or biological tool compounds is required. In bioindustrials, a proof of concept on MVP is required and in health tech, a scale-up ready MVP is required.
In collaboration with the BII team and our network of experts, you will make a gap-analysis for your start-up to find weak spots and roll out a development plan with every little step needed to reach the milestones on drug development, good manufacturing practice, regulatory strategy et cetera. The purpose of the 18-months long program is to build a case that can attract substantial funding. BII will fund up to seven companies in the program with a risk-free convertible loan of EUR 1.3M.
Read the program guidelines here.
Call opens
January 4, 2021
Deadline
February 23, 2021 at 14.00 CEST
Pitch day for invited applicants
May 6-11, 2021
Applicant notification
End-June, 2021
Earliest start date
September 1, 2021
Creation House Journey
Frederik Petursson Madsen
CEO, Cirqle BioMedical
“Becoming part of BioInnovation Institute has made a really big difference. They have managed to build a bridge that has lacked between research and venture capital. It has helped us attract talented people and put in place a solid plan that we are now executing, so we can create a new paradigm in contraception.”
Bo Tandrup
CEO, Lophora
“BII is the perfect platform for start-up companies in the life science field. During my +20 years in the industry I have founded and co-founded 6 companies, but I have never before had the level of support offered by BII. It’s not only access to seed capital, highly professional guidance in writing a business plan, and an outstanding global network for attracting funding; BII also offers office and lab facilities, legal advice, support with accounting and top-notch gourmet coffee.”
Ian Laquian
CEO and Co-founder, Kariya Pharma
“Our experiences and learnings from BII are less technical in nature, but rather denote the importance of community and (physical) proximity to innovators and facilitators. The BII provides us a world-class workspace to work from, where ideas and experiences are easily shared amongst like-minded entrepreneurs and industry experienced BII staff members. In our particular case, we are flanked by a number of CNS focused therapeutics companies that are all pretty much at the same stage of development. Hence, domain expertise, talent, experience, and support are always just meters away. This has helped us avoid reinventing the wheel many times over. Kariya is on the verge of initiating our regulatory toxicology studies, which is the final preclinical hurdle before going into human studies. “
Ph.D. Claus Elsborg Olesen
CEO, STipe Therapeutics
“Being a part of the BII creation house program has enabled STipe to recruit scientists with the diverse skills that have been essential for the further development of our leading technology for immune-oncology. While the BII team itself has helped us to establish and build relationships within the local and global biotech communities, culminating in a successful Series A round last October. Thanks to the BII we remain on track to deliver a first clinical candidate.”
Meet the Creation House team
Hervør Lykke Olsen
Creation House Lead
hlo@bii.dk
Christian Brix Tillegreen
Venture Lab Lead
cbt@bii.dk
Tony Cheng-fu Chang
Senior Business Developer
tch@bii.dk
Cathrine Nygaard Christensen
Funding Specialist
cnc@bii.dk
Start-ups we work with
Program partners
When joining the BII programs, start-ups become part of an international community focused on bringing ideas to life and science to the market.
I collaboration with our partners, we are looking to create value for the companies in BII’s programs and the ecosystem we are a part of. The partnerships are designed to support start-ups in their journey – and essentially increase the life science start-ups’ likelihood of success.
Meet our partners below and click on the read more button to find out more about what they offer start-ups in BII’s community.
Business Acceleration Partners
Back Bay’s expert guidance to companies at the earliest stages nourishes insight into the most promising science and technologies in development. They couple this with an exceptional understanding of development strategies globally, resulting in a true partnership for every stage of development.
Back Bay advisors and bankers bring their unique perspective through landscape analyses and patient journey, inflection points, capital raise planning, partnering, exit strategies, and much more. They can help figure out what to do and then get it done.
Find more information about them here.
Coulter Partners is a board and senior level executive search specialist focused exclusively on global Life Sciences. From their offices in the UK, Europe, North America and Asia-Pacific, they work together across boundaries and disciplines to build outstanding leadership teams for their clients in the pharmaceuticals, biotechnology, medical devices, diagnostics, health tech, CRO and services sectors. Their industry leading reputation is founded on deep sector knowledge and innovative thinking. Their strategy is built on a unique team culture and true global reach.
“Our goal is to bring you the world’s best talent.”
Find more information about them here
Innovayt helps BII start-ups and researchers obtain funding for their projects through high-quality grant and funding applications. Innovayt offer a broad range of services, including: identification and selection of funding opportunities; preparation and writing of effective funding applications; assistance for project management after approval; and training and public speaking related to innovation and finance. In their work with innovation funding, Innovayt can assist BII start-ups throughout all phases of projects, from ideation through application and submission to project management.
Find more information about them here.
Lyhne Life is specialized in communication for healthcare, medical, life sciences and biotech companies.
They work structured and agile with insights & strategy, creative development, implementation and activation. And they have no heavy and traditional apparatus, but instead a team of collaborating specialists with the skills required by the project.
They know that successful companies and strong brands need to evolve all the time – and they can help start-ups drive the development that creates positive change through communication.
Find more information about them here.
Plesner Law Firm is a contributing partner in the BII network and offers the BII start-ups free legal advice and expertise to avoid the many legal pitfalls that entrepreneurs face when starting a business. As part of the partnership, two lawyers from Plesner are present one day a week at the BII offices where they will provide consultancy and legal guidance.
Find more information about them here.
Zacco is a full-service intellectual property consultancy and contributing partner in the BII network. Zacco offers BII start-ups free advice and expertise on intellectual property rights to avoid legal pitfalls and to strengthen their position when looking for investors or cooperation partners.
Find more information about them here.
Program Advisory Group - Therapeutics
BII’s program advisory group / financing (VC) partnerships are focused on improving the likelihood of successful exists for our start-ups. The program advisory group of internationally-oriented VC companies are advising BII in the selection of start-ups for our programs.
Abingworth is a leading transatlantic life sciences investment firm. They help transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies.
Since 1973, Abingworth has invested in 168 life science companies, leading to 44 M&As and 69 IPOs. Their therapeutic focused investments fall into 3 categories: seed and early-stage, development stage, and clinical co-development.
Find more information about them here.
Novo Seeds is the early stage investment arm of Novo Holdings. Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.
Find more information about them here.
Novo Holdings is part of the Therapeutics, HealthTech and BioIndustrial Program Advisory Group.
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
Find more information about them here.
Sofinnova Partners is part of the Therapeutics, HealthTech and BioIndustrial Program Advisory Group.
New Enterprise Associates (NEA) is a global venture capital firm with a mission to make the world better by helping founders build great companies that improve the way we live, work and play.
NEA is part of the Therapeutics Program Advisory Group.
Read more about them here.
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies pursuing innovative science to significantly impact medical care. SR One’s team of investment professionals, located in the US and UK, have experience spanning basic science, drug development and commercialization. We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value. In its 30+ year history, SR One has invested >$1.1 billion in close to 190 companies, and its current portfolio includes 40+ private and public investments.
Find more information about them here‘
SR One is part of the Therapeutics Program Advisory Group.
Program Advisory Group - BioIndustrials
BII’s program advisory group / financing (VC) partnerships are focused on improving the likelihood of successful exists for our start-ups. The program advisory group of internationally-oriented VC companies are advising BII in the selection of start-ups for our programs.
Wellington Partners is a leading European Venture Capital firm investing in early – and growth stage life science companies. Wellington Partners is focused on investing in the most promising life science companies in the fields of biotechnology, therapeutics, medical technology, diagnostics and digital health. With funds totalling EUR 1 billion, and more than EUR 400 million committed to Life Sciences, Wellington Partners has been actively supporting world class private companies translating true innovation into successful businesses with exceptional growth. To date, Wellington Partners has invested in more than 40 innovative life science companies, including Actelion (acquired by J&J), Definiens (acquired by AZ/Medimmune), Invendo (acquired by Ambu), MTM laboratories (acquired by Roche), Rigontec (acquired by MSD), Symetis (acquired by Boston Scientific), Themis (acquired by MSD), Immatics and AMBOSS.
Wellington Partners is part of the BioIndustrial Program Advisory Group.
Find more information about them here.
Novo Seeds is the early stage investment arm of Novo Holdings. Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.
Find more information about them here.
Novo Holdings is part of the Therapeutics, HealthTech and BioIndustrial Program Advisory Group.
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
Find more information about them here.
Sofinnova Partners is part of the Therapeutics, HealthTech and BioIndustrial Program Advisory Group.
Program Advisory Group - Health Tech
BII’s program advisory group / financing (VC) partnerships are focused on improving the likelihood of successful exists for our start-ups. The program advisory group of internationally-oriented VC companies are advising BII in the selection of start-ups for our programs.
Novo Seeds is the early stage investment arm of Novo Holdings. Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.
Find more information about them here.
Novo Holdings is part of the Therapeutics, HealthTech and BioIndustrial Program Advisory Group.
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
Find more information about them here.
Sofinnova Partners is part of the Therapeutics, HealthTech and BioIndustrial Program Advisory Group.
BioVentures MedTech Funds invests in leading-edge medical technologies. Founded by the highly experienced team of BioVentures Investors, BioVentures MedTech Growth Capital Fund and BioVentures MedTech Innovation Fund target companies developing next-generation implantable and disposable devices, diagnostics, imaging, and digital health.
BioVentures Investors is part of the HealthTech Program Advisory Group.
Find more information about them here.
Rock Health exists to fund and support entrepreneurs working at the intersection of healthcare and technology. Put simply, Rock Health’s mandate is impact. Rock Health want to make healthcare massively better for every human being—driving down the cost to deliver improved services to more people. Massively better means incredible change—it’s improvement by an order of magnitude or more along every dimension—healthcare that is incredibly functional, reliable, convenient, and yes, inexpensive.
Find more information about them here.
Contact
Reach out to Senior Scientific Business Developer Hervør Lykke Olsen if you want to know more about the Creation House program.
Incubation environments
Inspired by successful incubation environments from around the world, BII offers your team incubation in our Copenhagen-facilities. Here you will be surrounded by like-minded researchers and entrepreneurs working on their projects in the open and collaborative environment at BII. In your daily work, your team will also have access to the capacities of the BII team, mentors, experts and our global network. We offer state of the art facilities in both open office space and open labs to meet your projects’ needs at desirable rates, which are covered by founder-friendly convertible loans.
BII is located in the heart of the Copenhagen Science City near life-science research institutions and start-up hubs.
Any questions? Read more on our FAQ section.
Stay up to date by signing up for our newsletter.
